For people with HIV and fatty liver on INSTI drugs, taking a placebo for a year leads to a 10.8% increase in belly fat.

For people with HIV and fatty liver who are taking INSTI drugs, taking tesamorelin made their belly fat decrease by 8.3% after a year, while those on a dummy pill saw their belly fat increase by 10.8%. This finding is from the abstract summary - full study details were not available

For people with HIV and fatty liver who are on INSTI drugs, taking tesamorelin for a year likely reduces belly fat by 8.3%, while those on a placebo see a 10.8% increase in belly fat.

Out of 61 people with HIV and fatty liver in the study, 39 were on INSTI drugs, and most of those (41%) were taking dolutegravir.

For people with HIV and fatty liver disease who are taking integrase inhibitor drugs, taking tesamorelin for a year likely helped reduce belly fat, while those on a placebo saw their belly fat increase.

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 31% compared to their starting point, which is much better than the tiny change seen in those on a placebo.